Skip to main content

Table 1 Efficacy Study 1. Summary of outcomes based on clinical and laboratory results

From: Efficacy of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine in cattle using a direct contact transmission model

Treatment Group N Percent Protected from Lesions (21 dpcc) Geometric mean FMDV A24/Cruzeiro/BRA/55 VNT titer (log10) ± SD on 7 dpv/0 dpcc (range) Percent Positive for FMDV A24/Cruzeiro/BRA/55 VNT on 7 dpv/0 dpcc Percent Protected from FMDV RNA in oral and nasal cavities (0–5 dpcc) Percent Positive for FMDV NSP Antibodies
Pedal only Pedal and Oronasal
T1: 1o vaccinated
AdtA24 5 × 1010 PU
(high dose)
Contact Challenge
6 83% 50% 2.2 ± 0.2a,b
(1.8–2.4)
100% 0% 0% - 0 dpcc
67% - 14 dpcc
T2: 1o vaccinated
AdtA24 1.25 × 1010 PU (medium dose)
Contact Challenge
6 100% 33% 1.5 ± 0.5a
(0.9–2.1)
100% 0% 0% - 0 dpcc
100% - 14 dpcc
T3: 1o vaccinated
AdtA24 3.125 × 109 PU (low dose)
Contact Challenge
6 67% 0% 1.1 ± 0.5b
(0.6–1.8)
67% 0% 0% - 0 dpcc
100% - 14 dpcc
T4: 1o naïve
Contact Challenge
(control)
4 0% 0% 0.6 ± 0.0* 0% 0% ND
T5 (IDL challenged seeder steers) 1 day prior to contact with T1-T4 8 0% 0% 0.6 ± 0.0* 0% 0% ND
  1. Dpcc days post contact challenge, DPV days post vaccination, VNT virus neutralization test, 1o primary, PU particle units, IDL intradermolingual challenge, ND Not Determined
  2. *A positive VNT is ≥0.9 log10. a, p = 0.01 for T1 > T2. b, p = < 0.001 for T1 > T3. p = 0.1 for T2 and T3